Hepatitis and Retrovirus

DiaSorin offers global blood screening and diagnostic solutions, with a wide range of instruments and highly sensitive and specific assays, on the ELISA format (including Murex Assay) and for the LIAISON® systems, including tests for HIV-1/2, HTLV, Hepatitis A, B, C, D, Syphilis and a wide range of other infectious diseases assays.

LIAISON® XL MUREX HBsAg Quant

The LIAISON® XL MUREX HBsAg Quant assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of hepatitis B surface antigen (HBsAg) in human serum or plasma samples. The test has to be performed on the LIAISON® XL analyzers only.

LIAISON® HBsAg

The LIAISON® HBsAg assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of hepatitis B surface antigen (HBsAg) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer only.

HBsAg Confirmatory Test

The HBsAg Confirmatory Test is an in vitro neutralization assay for confirmation of the presence of hepatitis B surface antigen (HBsAg) in human serum and plasma samples found repeatedly reactive for HBsAg by LIAISON® XL MUREX HBsAg Quant or LIAISON® HBsAg.

LIAISON® XL murex Anti-HBs

The LIAISON® XL Anti-HBs II assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of antibody to hepatitis B surface antigen (anti-HBs) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.

LIAISON® XL murex Anti-HBs Plus

The LIAISON® XL Anti-HBs II assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of antibody to hepatitis B surface antigen (anti-HBs) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.

LIAISON® Anti-HBc

The LIAISON® Anti-HBc assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of total antobodies to hepatitis B core antigen (anti-HBc) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.

LIAISON® HBc IgM

The LIAISON® HBc IgM assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of IgM immunoglobulim to hepatitis B core antigen (IgM anti-HBc) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.

LIAISON® HBeAg

The LIAISON® HBeAg assay uses chemiluminescent immunoassay (CLIA) technology for the quantitative determination of e antigen of hepatitis B virus (HBeAg) in human serum or plasma samples. HBeAg quantification may allow follow up of replicative activity/response to treatment (e.g. interferon) (20). The test has to be performed on the LIAISON® analyzer family.

LIAISON® Anti-HBe

The LIAISON® Anti-HBe assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of total antibodies to hepatitis B a antigen (anti-Bbe) in human serum or plasma samples. The test had to be perfomed on the LIAISON® analyzer family.

LIAISON® Anti-HAV

The LIAISON® Anti-HAV assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of total antibodies to hepatitis A virus (anti-HAV) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.

LIAISON® HAV IgM

The LIAISON® HAV IgM assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of IgM immunoglobulin to hepatitis A virus (IgM anti-HAV) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.

LIAISON® XL MUREX HCV Ab

The LIAISON® XL MUREX HCV Ab assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific antibodies to hepatitis C virus (anti-HCV) in human serum or plasma samples. The test has to be performed on the LIAISON® XL analyzers only.

LIAISON® XL MUREX HIV Ab / Ag

The LIAISON® XL MUREX HIV Ab / Ag assay uses chemiluminescence immunoassay (CLIA) technology for the combined qualitative determination of p24 antigen of human immunodeficiency virus type 1 (HIV-1) and specific antibodies to both human immunodeficiency virus type 1 (group M and group O) and/or human immunodeficiency virus type 2 (HIV-2) in human serum or plasma samples. The test has to be performed on the LIAISON® XL analyzers only.

LIAISON® XL MUREX HIV Ab/Ag HT

The LIAISON® XL murex HIV Ab / Ag HT assay uses chemiluminescence immunoassay (CLIA) technology for the combined qualitative determination of p24 antigen of human immunodeficiency virus type 1 (HIV-1) and specific antibodies to both human immunodeficiency virus type 1 (group M and group O) and/or human immunodeficiency virus type 2 (HIV-2) in human serum or plasma samples.
The LIAISON® XL murex HIV Ab / Ag HT assay is intended to be used as an aid in the diagnosis of HIV-1/HIV-2 infection and as a screening test for donated blood and plasma.
The test has to be performed on the LIAISON® XL Analyzer only.

LIAISON® XL recHTLV-I/II

The LIAISON® XL MUREX recHTLV-I/II assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific antibodies to Human T-cell Lymphotropic Virus (HTLV) type I and type II (anti-HTLV-I and anti-HTLV-II) in human serum or plasma samples.
The test has to be performed on the LIAISON® XL analyzer only.

 

Discover LIAISON® XL Hepatitis and Retrovirus
LIAISON® XL MUREX Anti-HDV

The LIAISON® XL murex Anti-HDV assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative detection of total antibodies
to hepatitis D virus in human serum and plasma samples. The assay results, in conjunction with other laboratory results and clinical information,
are intended to be used as an aid in the diagnosis of HDV infection and as a screening test for organ and tissue donors.

Murex HBsAg Version 3

Enzyme immunoassay for the detection of hepatitis B surface antigen in human serum or plasma.

Murex HBsAg Confirmatory Version 3

For the confirmation of the presence of hepatitis B surface antigen in human serum and plasma samples. To be used on serum or plasma samples found to be reactive in the Murex HBsAg Version 3 (9F80) assay.

Murex anti-HBc (total)

Enzyme immunoassay for the detection of antibodies to hepatitis B core antigen (anti-HBc) in human serum or plasma.

Murex anti-HCV (version 4.0)

An enzyme immunoassay for the detection of antibodies to hepatitis C virus (HCV) in human serum or plasma.

Murex HCV Ag/Ab Combination

Immunoassay for the simultaneous detection of hepatitis C (HCV) core antigen and anti-HCV antibodies in human serum or plasma.

Murex HIV Ag/Ab Combination

Enzyme immunoassay for improved detection of seroconversion to human immunodeficiency virus types 1 (HIV-1, HIV-1 group O) and detection of anti-HIV-2 antibodies in human serum or plasma.

Murex HIV-1.2.O

Enzyme immunoassay for the detection of antibodies to human immunodeficiency virus types 1 (HIV-1, HIV-1 group O) and 2 (HIV-2) in human serum or plasma.

Murex HTLV I + II

A qualitative enzyme immunoassay for the detection of antibodies against human T-lymphotropic virus types I and II (HTLV-I and HTLV-II) in human serum and plasma.

ICE* Syphilis

Enzyme immunoassay for the detection of antibodies against Treponema pallidum in human serum and plasma.

Discover ELISA Murex Menu

Download the Brochure

ETI-AB-HAVK PLUS (anti-HAV)
ETI-HA-IGMK PLUS (HAV IgM)
Murex HBsAg Version 3
Murex HBsAg Version 3 Confirmatory
ETI-AB-AUK-3 (anti-HBs)
Murex Anti-HBc (Total)
ETI-AB-COREK PLUS (anti-HBc)
ETI-CORE-IGMK PLUS (anti-HBc IgM)
ETI-AB-EBK PLUS (anti-HBe)
ETI-EBK PLUS (HBeAg)
Murex anti-HCV (version 4.0)
Murex HCV Ag/Ab Combination
HCV Blot 3.0** (anti-HCV)
ETI-AB-DELTAK-2 (anti-HD)
ETI-DELTAK-2 (HDAg)
ETI-DELTA-IGMK-2 (IgM anti-HD)
Anti-HEV IgG **
Anti-HEV IgM **
Murex HIV Ag/Ab Combination (HIV Ag/Ab)
Murex HIV 1.2.O (anti-HIV-1/2)
HIV Blot 2.2** (anti-HIV-1/2)
HIV-1 BLOT 1.3** (anti-HIV-1)
HIV-2 BLOT 1.2** (anti-HIV-2)
Murex HTLV I+II
HTLV BLOT 2.4** (anti-HTLV-I/II)
ICE* Syphilis
CHAGAS (Tripanosoma cruzi) IgG**
ELISA CHAGAS III**

 

Viral hepatitis is a disease of major significance in terms of morbidity and mortality. In most cases, hepatitis is a disease that is not discriminating and selective to limited geographical groups or social and socioeconomic factors. So it is necessary that the physician, the clinician and other health care professionals know how to diagnose and monitor viral hepatitis. 150 million people are chronically infected with the virus of Hepatitis C, 2 billion people (estimated) worldwide have been infected with the Hepatitis B virus and 1.4 million estimated cases of Hepatitis A occur annually.
Retrovirus is a family which includes the well-known human immunodeficiency virus (HIV) and Human T-cell Leukemia Virus I and II (HTLV-I and II). Almost half the people infected with HIV do not know it until they are diagnosed with AIDS. Therefore early identification of HIV-positive individuals, monitoring of viral load and resistance testing can improve patient outcomes and reduce disease transmission. Around 34 million people are living with HIV.
Laboratory tests are therefore essential to provide clinicians with the tools to improve patient management.
About 92 million blood donations are collected every year worldwide, and an adequate and reliable supply of safe blood can be assured by putting in place guidelines on the appropriate clinical use of blood, haemovigilance system to monitor and improve the safety of the transfusion process and the testing of all the blood units for HIV, HCV, HBV, Syphilis, and, in some countries, Chagas and HTLV I/II.